COVID-19: NGO Commends Nana Addo For Suspending Foreign Travels For Gov’t Officials
The Management and Board of Community Focus Foundation Ghana (CFF-GH) has applauded the President of Ghana, H.E Nana Addo Dankwa...
New CRISPR Tool Fixes CFTR Mutations in CF Patients’ Stem Cells, Study Finds
A new variation of the gene-editing technology CRISPR-Cas9 can correct mutations in the CFTR gene — the genetic cause of cystic fibrosis...
New drugs aim to disarm the immune system’s ‘atomic bomb’ cells
Seeking a new treatment for people who have dangerous blockages in their coronary arteries, doctors in London are trying to disarm the...
Inhaled Messenger RNA Treatment Fast-Tracked for Cystic Fibrosis
The Food and Drug Administration has granted Fast Track designation to MRT5005 (Translate Bio), an inhaled messenger RNA (mRNA)...
COVID-19 in Chronic Lung Disease: What You Need to Know
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and novel coronavirus disease (COVID-19) have been of major concern to the...
This new treatment helps 90% of cystic fibrosis patients breathe better
Vertex’s Trikafta was the second-fastest FDA approval in history, and could help some 27,000 patients. In October 2019, Vertex...
CFTR Amplifiers May Be Potent CF Mono or Combo Therapy, Study Says
Amplifiers, a potential new class of therapies that modify CFTR — the protein whose defects cause cystic fibrosis (CF) — do so by...
UK NICE to Announce Decision on Vertex’s Therapy Trikafta in December
The National Institute for Health and Care Excellence (NICE) in the U.K. is currently in the process of evaluating Vertex...
FDA Grants Fast Track Status to Translate Bio’s RNA-Based Therapy MRT5005
The U.S. Food and Drug Administration (FDA) has granted fast track designation to MRT5005, an investigational RNA-based treatment for...
Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO® (ivacaftor) will be available to eligible patients with...
